(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.47%) $27.23
(0.41%) $924.25
(0.32%) $0.935
(0.80%) $11.04
(0.13%) $0.800
(-0.32%) $91.87
5 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 7.54%
@ $1.790
Issued: 14 Feb 2024 @ 09:30
Return: 21.23%
Previous signal: Feb 13 - 09:30
Previous signal:
Return: 1.71 %
Live Chart Being Loaded With Signals
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness...
Stats | |
---|---|
Today's Volume | 343 130 |
Average Volume | 918 337 |
Market Cap | 553.21M |
EPS | $0 ( 2024-02-27 ) |
Next earnings date | ( $-0.200 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.33 |
ATR14 | $0.00300 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-09 | Lang Matthew | Buy | 500 000 | Option (right to buy) |
2024-02-09 | Lang Matthew | Buy | 50 000 | Common Stock |
2024-02-09 | Hill Stephen J. | Buy | 400 000 | Stock Option (right to buy) |
2024-02-09 | Hill Stephen J. | Buy | 40 000 | Common Stock |
2024-02-09 | Lee Gary K. | Buy | 400 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
39.79 |
Last 94 transactions |
Buy: 113 687 542 | Sell: 91 558 207 |
Volume Correlation
Lyell Immunopharma, Inc. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Lyell Immunopharma, Inc. Correlation - Currency/Commodity
Lyell Immunopharma, Inc. Financials
Annual | 2023 |
Revenue: | $130 000 |
Gross Profit: | $-20.12M (-15 476.92 %) |
EPS: | $-0.930 |
FY | 2023 |
Revenue: | $130 000 |
Gross Profit: | $-20.12M (-15 476.92 %) |
EPS: | $-0.930 |
FY | 2022 |
Revenue: | $84.68M |
Gross Profit: | $68.22M (80.55 %) |
EPS: | $-0.0192 |
FY | 2021 |
Revenue: | $10.65M |
Gross Profit: | $10.65M (100.00 %) |
EPS: | $-1.249 |
Financial Reports:
No articles found.
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators